Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2020-06-22 Director's Dealing
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-06-22 English
SC 13D/A
Major Shareholding Notification
2020-06-17 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-17 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. The content includes announcements about the departure and election of directors and officers, shareholder voting results at the Annual Meeting, and approval of a long-term incentive plan. The key section is Item 5.02 and Item 5.07, which relate to changes in the company's board of directors and officers, and submission of matters to a vote of security holders. There is no detailed financial data or comprehensive financial statements, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy statement itself but references it. The primary focus is on management and board changes and voting results. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). Although voting results are included, the document is primarily about director changes and related matters, so MANG is the best fit. The document length (6505 characters) and content confirm it is a substantive filing, not just an announcement of a report publication or certification. Therefore, the classification is MANG with high confidence.
2020-06-16 English
S-8 Filing
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Regeneron Pharmaceuticals, Inc. on June 16, 2020. It registers additional shares under the company's 2014 Long-Term Incentive Plan. The document includes details about the securities to be registered, signatures of company officers, and an exhibit index. Form S-8 is a registration statement used for securities issued under employee benefit plans and is related to share issuance and capital changes. It is not a financial report, earnings release, or management discussion. Therefore, the document fits the category of Share Issue/Capital Change announcements.
2020-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.